REG - RUA Life Sciences - Result of AGM

Rua Life SciencesAnnouncement

16/08/2022 18:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220816:nRSP2352Wa&default-theme=true

RNS Number : 2352W  RUA Life Sciences PLC  16 August 2022

16 August 2022

RUA Life Sciences plc

("RUA", the "Company" or the "Group")

Result of AGM

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical
device businesses focused on the exploitation of the world's leading long-term
implantable biostable polymer (Elast-Eon(TM)), announces that all resolutions
put forward to its Annual General Meeting held earlier today were duly passed
and the votes cast were as follows:

 

 Res No.  Votes For  %        Votes Against  %      Votes Total  % I.S.C.  Votes Withheld
 01       2,517,502  100.00%  0              0.00%  2,517,502    11.35     11,763
 02       1,164,389  96.51%   42,142         3.49%  1,206,531    5.44      1,322,734
 03       2,517,502  100.00%  0              0.00%  2,517,502    11.35     11,763
 04       2,517,502  100.00%  0              0.00%  2,517,502    11.35     11,763
 05       1,900,843  94.80%   104,178        5.20%  2,005,021    9.04      524,244
 06       2,413,324  95.86%   104,178        4.14%  2,517,502    11.35     11,763
 07       2,517,487  100.00%  15             0.00%  2,517,502    11.35     11,763
 08       2,508,972  99.66%   8,530          0.34%  2,517,502    11.35     11,763
 09       2,404,481  95.51%   112,921        4.49%  2,517,402    11.35     11,863
 10       2,404,385  95.51%   112,921        4.49%  2,517,306    11.35     11,959

 

 

For further information contact:

 

RUA Life Sciences

Bill Brown, Chairman
                         Tel: +44 (0)1294 317073

Dr Caroline Stretton, Group MD
            Tel: +44 (0)1294 317073

 

Cenkos Securities plc (Nominated Adviser and Broker)   Tel: +44 (0)20
7397 8900

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device business. RUA
Life Sciences is the holding company of the Group's four trading businesses,
each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life Sciences
business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 

 RUA Medical:           End-to-end contract developer and manufacturer of medical devices and
                        implantable fabric specialist.

 RUA Biomaterials:      Licensor of Elast-Eon(TM) polymers to the medical device industry.

 RUA Vascular:          Commercialisation of open surgical vascular grafts and patches

 RUA Structural Heart:  Development of polymeric leaflet systems for heart valves.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPFMRTMTMBBAT